Get the latest news, insights, and market updates on BVS (Bioventus Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Bioventus Q4 Earnings Call Highlights
Bioventus (NASDAQ:BVS) executives told investors the company closed 2025 with what leadership described as a “solid quarter” and a “pivotal year,” highlighting stronger organic growth, higher profitability, and record quarterly operating cash flow while laying out a 2026 plan to step up investment i Mar 5, 2026 - $BVS
Bioventus (BVS) Q4 2025 Earnings Call Transcript
Rob will begin his remarks with an update on our business, review our performance against our 2025 priorities, and lay out our 2026 objectives. Then Mark will review the fourth quarter results and discuss our 2026 financial guidance. Before we begin, I would like to remind everyone that our remarks today contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the company's filings with the SEC, including Item 1A, Risk Factors, of the company's Form 10-K for the year ended December 31, 2025, as such factors may be updated from time to time in the company's other filings made with the SEC. Mar 5, 2026 - $BVS
Bioventus: Q4 Earnings Snapshot
The Durham, North Carolina-based company said it had profit of 21 cents per share. Earnings, adjusted for non-recurring costs, were 24 cents per share. The company posted revenue of $157.9 million in the period. Mar 5, 2026 - $BVS
Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results
Q4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0%Fourth quarter GAAP earnings of $0.21 per diluted share compared to $0.00 in the prior-year periodNon-GAAP earnings* of $0.24 per diluted shareFourth quarter cash from operations of $38.0 million increased 97%2026 financial guidance reflects continued above-market revenue growth, higher earnings and robust cash generation DURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Biovent Mar 5, 2026 - $BVS
Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026
DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2025 before the market opens on Thursday, March 5, 2026. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial Feb 24, 2026 - $BVS
Bioventus Details Turnaround Plan, Four Growth Drivers at J.P. Morgan Conference
Bioventus (NASDAQ:BVS) executives outlined a multi-year turnaround story and a set of new growth priorities during a presentation and Q&A session hosted by J.P. Morgan healthcare analyst David Brumund. CEO Rob Claypoole and CFO Mark Singleton emphasized recent margin and cash flow improvements, Jan 16, 2026 - $BVS
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple